RE:RE:RE:RE:RE:RE:MonographNo doubt, LABS is signing up customers, be it Germany, South America, Canada or the U.S. All those customers have one thing in common....buying cannabinoid pharmaceutical grade API's. Add to that all of the clincal trials they have in their pipeline.
What does their global pharmaceutical 'partner' do in a case like that? Stand by and watch or become more proactive/involed with that business model? I see a perfect fit with Pfizer because they also offer white label services, including selling API's through their PC1 division.
To me, the fit and synergies are a no brainer....time will tell...hopeful more revealed with the drug monograph and/or an in your face approach with news on their, 'for competitive reasons' who that big fish is.
ps: Personally, I feel it must be something very big to not reveal their global pharma partner...more than just a generic of Epidiolex...something much bigger than that....time will, don't know, have to live life and learn.